Stifel Cuts MDT Target to $95, Cites MiniMed IPO Effects

Medtronic plc (NYSE:MDT) is included among the 15 Best Consistent Dividend Stocks to Buy Right Now.

On April 6, Stifel lowered its price recommendation on Medtronic plc (NYSE:MDT) to $95 from $105. It reiterated a Hold rating on the shares. The firm updated its model to reflect expected transaction-related impacts following the March 9 completion of Medtronic’s Diabetes business IPO, now called “MiniMed” (MMED). Medtronic had indicated that MiniMed will remain a consolidated subsidiary within MDT until the formal separation, which is expected about six months after the IPO. During this transition period, Stifel continues to model the full Diabetes business revenue. At the same time, it adjusts for the 10% non-controlling interest that Medtronic sold in the IPO. Management expects IPO-related EPS dilution of 1c to 2c per month until the separation is complete.

On March 27, Reuters reported that Medtronic announced the US Food and Drug Administration had cleared its surgical system for cranial and ear, nose, and throat procedures. This expands the platform beyond the spine indication it received earlier in the year. The system, called Stealth AXiS, combines surgical navigation, imaging, and robotics to assist surgeons during complex procedures.

For cranial surgeries, it uses artificial intelligence to automatically generate brain maps and highlight key neural pathways, helping guide planning and execution. For ENT procedures, it offers more precise navigation along with clearer visualization of the sinuses and skull base.

Medtronic plc (NYSE:MDT) is an Ireland-based healthcare technology provider. Its products are organized across four main portfolios: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes.

READ NEXT: 15 Cheapest Stocks with Highest Dividends and 14 Cheap DRIP Stocks to Buy Now

Disclosure: None. Follow Insider Monkey on Google News.